Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection

Molina et al., Médecine et Maladies Infectieuses, 50:4, doi:10.1016/j.medmal.2020.03.006 (date from preprint)
Mar 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19hcq.org
Report on 11 patients treated with HCQ with no control group. Authors suggest there is no evidence of benefit for HCQ based on PCR+ results for 8/10 patients at day 5-6. Binary PCR evaluation with an unknown Ct. Binary PCR does not distinguish replication-competence.
Molina et al., 28 Mar 2020, peer-reviewed, 7 authors.
This PaperHCQAll
Abstract: See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/340293105 No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection Article in Médecine et Maladies Infectieuses · March 2020 DOI: 10.1016/j.medmal.2020.03.006 CITATIONS READS 341 1,047 7 authors, including: Constance Delaugerre Breno Melo-Lima Assistance Publique – Hôpitaux de Paris Paris Diderot University-INSERM 172 PUBLICATIONS 4,647 CITATIONS 8 PUBLICATIONS 361 CITATIONS SEE PROFILE SEE PROFILE Lauriane Goldwirt Nathalie De Castro Hôpital Saint-Louis (Hôpitaux Universitaires Saint-Louis, Laboisière, Fernand-Widal) Hôpital Saint-Louis (Hôpitaux Universitaires Saint-Louis, Laboisière, Fernand-Widal) 63 PUBLICATIONS 962 CITATIONS 82 PUBLICATIONS 1,789 CITATIONS SEE PROFILE Some of the authors of this publication are also working on these related projects: ANRS 138 EASIER trial View project ANRS-PREVENIR View project All content following this page was uploaded by Breno Melo-Lima on 15 April 2020. The user has requested enhancement of the SEE PROFILE G Model MEDMAL-4279; No. of Pages 2 ARTICLE IN PRESS Médecine et maladies infectieuses xxx (2020) xxx–xxx Disponible en ligne sur ScienceDirect www.sciencedirect.com Letter to the editor No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection The COVID-19 epidemic is the worst worldwide pandemic in a century with more than 500,000 cases and 25,000 deaths so far. In France, more than 30,000 cases have been reported up to March 27, and nearly 2000 have died. Pending the availability of a vaccine, there is a critical need to identify effective treatments and a number of clinical trials have been implemented worldwide. Chloroquine analogs have been shown to inhibit the acidification of endosomes and to exhibit in vitro a non-specific antiviral activity at high micromolar concentration against a broad range of emerging virus (HIV, dengue, hepatitis C, chikungunya, influenza, Ebola, SARS and MERS viruses) and more recently COVID-19 [1,2]. In France, following the results of a clinical study in Marseille, there is considerable interest for the use of hydroxychloroquine to treat COVID-19 disease, and the French Ministry of Health recently allowed the use of hydroxychloroquine to treat COVID-19 disease pending the results of ongoing clinical trials [3]. In their study, Gautret et al. reported a 100% viral clearance in nasopharyngeal swabs in 6 patients after 5 and 6 days of the combination of hydroxychloroquine and azithromycin [3]. This rate of viral clearance was lower with hydroxychloroquine alone (57.1%) and was only 12.5% in patients who did not receive hydroxychloroquine (P < 0.001). Such a rapid and full viral clearance was quite unexpected and we wished to assess in a prospective study virologic and clinical outcomes of 11 consecutive patients hospitalised in our department who received hydroxychloroquine (600 mg/d for 10 days) and azithromycin (500 mg day 1 and 250 mg days 2 to 5) using the same dosing regimen reported by Gautret et al. [3]. There were 7 men and 4 women with a mean age of 58.7 years (range: 20–77), 8 had significant comorbidities associated with poor outcomes (obesity: 2; solid cancer: 3; hematological cancer: 2;..
{ 'indexed': {'date-parts': [[2024, 5, 17]], 'date-time': '2024-05-17T20:14:55Z', 'timestamp': 1715976895832}, 'reference-count': 8, 'publisher': 'Elsevier BV', 'issue': '4', 'license': [ { 'start': { 'date-parts': [[2020, 6, 1]], 'date-time': '2020-06-01T00:00:00Z', 'timestamp': 1590969600000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2021, 5, 13]], 'date-time': '2021-05-13T00:00:00Z', 'timestamp': 1620864000000}, 'content-version': 'am', 'delay-in-days': 346, 'URL': 'http://www.elsevier.com/open-access/userlicense/1.0/'}], 'content-domain': { 'domain': ['clinicalkey.fr', 'em-consulte.com', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2020, 6]]}, 'DOI': '10.1016/j.medmal.2020.03.006', 'type': 'journal-article', 'created': {'date-parts': [[2020, 3, 30]], 'date-time': '2020-03-30T14:58:09Z', 'timestamp': 1585580289000}, 'page': '384', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 519, 'title': 'No evidence of rapid antiviral clearance or clinical benefit with the combination of ' 'hydroxychloroquine and azithromycin in patients with severe COVID-19 infection', 'prefix': '10.1016', 'volume': '50', 'author': [ {'given': 'J.M.', 'family': 'Molina', 'sequence': 'first', 'affiliation': []}, {'given': 'C.', 'family': 'Delaugerre', 'sequence': 'additional', 'affiliation': []}, {'given': 'J.', 'family': 'Le Goff', 'sequence': 'additional', 'affiliation': []}, {'given': 'B.', 'family': 'Mela-Lima', 'sequence': 'additional', 'affiliation': []}, {'given': 'D.', 'family': 'Ponscarme', 'sequence': 'additional', 'affiliation': []}, {'given': 'L.', 'family': 'Goldwirt', 'sequence': 'additional', 'affiliation': []}, {'given': 'N.', 'family': 'de Castro', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.medmal.2020.03.006_bib0045', 'doi-asserted-by': 'crossref', 'first-page': '269', 'DOI': '10.1038/s41422-020-0282-0', 'article-title': 'Remdesivir and chloroquine effectively inhibit the recently emerged ' 'novel coronavirus (2019-nCoV) in vitro', 'volume': '30', 'author': 'Wang', 'year': '2020', 'journal-title': 'Cell Res'}, { 'key': '10.1016/j.medmal.2020.03.006_bib0050', 'doi-asserted-by': 'crossref', 'first-page': 'e00293', 'DOI': '10.1002/prp2.293', 'article-title': 'Targeting endosomal acidification by chloroquine analogs as a promising ' 'strategy for the treatment of emerging viral diseases', 'volume': '5', 'author': 'Al-Bari', 'year': '2017', 'journal-title': 'Pharmacol Res Perspect'}, { 'key': '10.1016/j.medmal.2020.03.006_bib0055', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.ijantimicag.2020.105949', 'article-title': 'Hydroxychloroquine and azithromycin as a treatment of COVID-19: results ' 'of an open-label non-randomised clinical trial', 'author': 'Gautret', 'year': '2020', 'journal-title': 'Int J Antimicrob Agents'}, { 'key': '10.1016/j.medmal.2020.03.006_bib0060', 'first-page': '03-', 'article-title': 'A pilot study of hydroxychloroquine in treatment of patients with ' 'common coronavirus disease-19 COVID-19)', 'volume': '03', 'author': 'Chen', 'year': '2020', 'journal-title': 'J Zhejiang Univ Sci'}, { 'key': '10.1016/j.medmal.2020.03.006_bib0065', 'doi-asserted-by': 'crossref', 'first-page': '268', 'DOI': '10.3390/v10050268', 'article-title': 'Paradoxical effect of chloroquine treatment in enhancing Chikungunya ' 'virus infection', 'volume': '10', 'author': 'Roques', 'year': '2018', 'journal-title': 'Viruses'}, { 'key': '10.1016/j.medmal.2020.03.006_bib0070', 'doi-asserted-by': 'crossref', 'first-page': 'e785', 'DOI': '10.1371/journal.pntd.0000785', 'article-title': 'A randomised controlled trial of chloroquine for the treatment of ' 'dengue in Vietnamese adults', 'volume': '4', 'author': 'Tricou', 'year': '2010', 'journal-title': 'PLos Neglected Trop Dis'}, { 'key': '10.1016/j.medmal.2020.03.006_bib0075', 'doi-asserted-by': 'crossref', 'first-page': '677', 'DOI': '10.1016/S1473-3099(11)70065-2', 'article-title': 'Chloroquine for influenza prevention: a randomised, double-blind, ' 'placebo-controlled trial', 'volume': '11', 'author': 'Paton', 'year': '2011', 'journal-title': 'Lancet Infect Dis'}, { 'key': '10.1016/j.medmal.2020.03.006_bib0080', 'doi-asserted-by': 'crossref', 'first-page': '353', 'DOI': '10.1001/jama.2012.6936', 'article-title': 'Effects of hydroxychloroquine on immune activation and disease ' 'progression among HIV-infected patients not receiving antiretroviral ' 'therapy: a randomised controlled trial', 'volume': '308', 'author': 'Paton', 'year': '2012', 'journal-title': 'JAMA'}], 'container-title': 'Médecine et Maladies Infectieuses', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S0399077X20300858?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S0399077X20300858?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2021, 9, 21]], 'date-time': '2021-09-21T16:29:45Z', 'timestamp': 1632241785000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S0399077X20300858'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 6]]}, 'references-count': 8, 'journal-issue': {'issue': '4', 'published-print': {'date-parts': [[2020, 6]]}}, 'alternative-id': ['S0399077X20300858'], 'URL': 'http://dx.doi.org/10.1016/j.medmal.2020.03.006', 'relation': {}, 'ISSN': ['0399-077X'], 'subject': [], 'container-title-short': 'Médecine et Maladies Infectieuses', 'published': {'date-parts': [[2020, 6]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'No evidence of rapid antiviral clearance or clinical benefit with the ' 'combination of hydroxychloroquine and azithromycin in patients with severe ' 'COVID-19 infection', 'name': 'articletitle', 'label': 'Article Title'}, { 'value': 'Médecine et Maladies Infectieuses', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.medmal.2020.03.006', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'simple-article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2020 Elsevier Masson SAS. All rights reserved.', 'name': 'copyright', 'label': 'Copyright'}]}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit